All In Biotech

Drug Trial Radar · NCT06829199

A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)

A Phase 2, Umbrella Study to Evaluate the Safety, Tolerability, and Clinical Activity of Investigational Agents for Newly Diagnosed, High-Risk, Early-Stage Triple-Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Mar 26, 2025

Primary completion

Jan 18, 2029

Study completion Mar 18, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers want to learn if giving boserolimab (MK-5890) with standard treatment (pembrolizumab and chemotherapy) before surgery can help treat triple negative breast cancer (TNBC). The goals of this study are to learn about the safety of boserolimab given with standard treatment before surgery and to learn if people tolerate it and how many people have no signs of cancer in the tissues and lymph nodes removed during surgery.

Conditions

  • Early Triple Negative Breast Cancer

Interventions

  • PembrolizumabBiological

    Neoadjuvant therapy - 200 mg intravenous (IV) infusion every 3 weeks (Q3W) for up to approximately 24 weeks Adjuvant therapy - 200 mg IV infusion Q3W or 400 mg IV infusion every 6 weeks (Q6W) for up to approximately 30 weeks.

  • PaclitaxelDrug

    80 mg/m\^2 by IV infusion every week for up to 12 weeks.

  • CarboplatinDrug

    AUC 1.5 mg/mL/min by IV infusion every week for up to 12 weeks.

  • Doxorubicin (hydrochloride)Drug

    60 mg/m\^2 by IV infusion Q3W for up to 12 weeks.

  • BoserolimabBiological

    30 mg by IV infusion every 6 weeks (Q6W) for up to 12 Weeks.

  • Epirubicin HydrochlorideDrug

    90 mg/m\^2 by IV infusion every 3 weeks (Q3W) for up to 12 weeks.

  • CyclophosphamideDrug

    600 mg/m\^2 by IV infusion every 3 weeks (Q3W) for up to 12 weeks.

  • CapecitabineDrug

    1000 mg/m\^2 to 1250 mg/m\^2 by oral administration twice a day (2 weeks on and 1 week off) for up to approximately 24 weeks.

  • Olaparib (if approved/available locally)Drug

    300 mg by oral administration twice a day for up to approximately 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with one or more adverse events (AEs)Time frame: Up to approximately 34 months
  2. Number of participants who discontinue study intervention due to an AETime frame: Up to approximately 27 months
  3. Pathological complete response (pCR) rate at the time of definitive surgeryTime frame: Up to approximately 9 months

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Optum Care Cancer Center ( Site 0004)

    Las Vegas, Nevada

  • National Cheng Kung University Hospital ( Site 0901)

    Tainan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.